AEZS
$0.33
Aeterna Zentaris
($.02)
(6.41%)
AEZS
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.02)
Revenue:  $0.60 Mil
Thursday
Feb 3
4:05 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AEZS reports earnings?
Beat
Meet
Miss

Where is AEZS's stock price going from here?
Up
Flat
Down
Stock chart of AEZS
Analysts
Summary of analysts' recommendations for AEZS
Score
Grade
Pivots
Resistance
$0.36
$0.35
$0.34

$0.33

Support
$0.32
$0.31
$0.30
Tweet
Growth
Description
AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers.
Peers
Vertex PharmaceuticalsMerck & Co.Ultragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisEli LillyPfizerInterCept